# Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

> **NCT04630730** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 46 (estimated)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC)
- **DRUG:** Atezolizumab
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT04630730
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-24
- **Primary completion:** 2026-06
- **Final completion:** 2030-06
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04630730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04630730, "Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04630730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*